Literature DB >> 20822351

Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses.

Moses O Oyewumi1, Amit Kumar, Zhengrong Cui.   

Abstract

The development of novel immune adjuvants is emerging as a significant area of vaccine delivery based on the continued necessity to amplify immune responses to a wide array of new antigens that are poorly immunogenic. This article specifically focuses on the application of nanoparticles and microparticles as vaccine adjuvants. Many investigators are in agreement that the size of the particles is crucial to their adjuvant activities. However, reports on correlating the size of particle-based adjuvants and the resultant immune responses have been conflicting, with investigators on both sides of the fence with impressive data in support of the effectiveness of particles with small sizes (submicron) over those with larger sizes (micron) and vice versa, while other investigators reported data that showed submicron- and micron-sized particles are effective to the same degree as immune adjuvants. We have generated a list of biological, immunological and, more importantly, vaccine formulation parameters that may have contributed to the inconsistency from different studies and made recommendations on future studies attempting to correlate the size of particulate adjuvants and the immune responses induced. The information gathered could lead to strategies to optimize the performance of nano-microparticles as immune adjuvants.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20822351      PMCID: PMC2963573          DOI: 10.1586/erv.10.89

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  100 in total

Review 1.  Microparticles as vaccine adjuvants and delivery systems.

Authors:  Derek T O'Hagan; Manmohan Singh
Journal:  Expert Rev Vaccines       Date:  2003-04       Impact factor: 5.217

2.  Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors.

Authors:  Theodora Fifis; Anita Gamvrellis; Blessing Crimeen-Irwin; Geoffrey A Pietersz; Jie Li; Patricia L Mottram; Ian F C McKenzie; Magdalena Plebanski
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

Review 3.  Vaccine adjuvants: current state and future trends.

Authors:  Nikolai Petrovsky; Julio César Aguilar
Journal:  Immunol Cell Biol       Date:  2004-10       Impact factor: 5.126

4.  Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target.

Authors:  Monika Manocha; Pramod Chandra Pal; K T Chitralekha; Beena Elizabeth Thomas; Vinita Tripathi; Siddhartha Dutta Gupta; Ramesh Paranjape; Smita Kulkarni; D Nageswara Rao
Journal:  Vaccine       Date:  2005-07-27       Impact factor: 3.641

5.  Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides.

Authors:  Klaus Zwiorek; Carole Bourquin; Julia Battiany; Gerhard Winter; Stefan Endres; Gunther Hartmann; Conrad Coester
Journal:  Pharm Res       Date:  2007-10-03       Impact factor: 4.200

6.  Influence of the stabilizer coating layer on the purification and freeze-drying of poly(D,L-lactic acid) nanoparticles prepared by an emulsion-diffusion technique.

Authors:  D Quintanar-Guerrero; A Ganem-Quintanar; E Allémann; H Fessi; E Doelker
Journal:  J Microencapsul       Date:  1998 Jan-Feb       Impact factor: 3.142

7.  Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.

Authors:  Z Shen; G Reznikoff; G Dranoff; K L Rock
Journal:  J Immunol       Date:  1997-03-15       Impact factor: 5.422

8.  Topical immunization using nanoengineered genetic vaccines.

Authors:  Zhengrong Cui; Russell J Mumper
Journal:  J Control Release       Date:  2002-05-17       Impact factor: 9.776

9.  Towards preserving the immunogenicity of protein antigens carried by nanoparticles while avoiding the cold chain.

Authors:  Brian R Sloat; Michael A Sandoval; Zhengrong Cui
Journal:  Int J Pharm       Date:  2010-04-21       Impact factor: 5.875

10.  Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin.

Authors:  Antonella Caputo; Egidio Brocca-Cofano; Arianna Castaldello; Rebecca Voltan; Riccardo Gavioli; Indresh K Srivastava; Susan W Barnett; Aurelio Cafaro; Barbara Ensoli
Journal:  Vaccine       Date:  2008-01-15       Impact factor: 3.641

View more
  112 in total

1.  Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design.

Authors:  Xinran Li; Brian R Sloat; Nijaporn Yanasarn; Zhengrong Cui
Journal:  Eur J Pharm Biopharm       Date:  2010-12-21       Impact factor: 5.571

Review 2.  Key roles of adjuvants in modern vaccines.

Authors:  Steven G Reed; Mark T Orr; Christopher B Fox
Journal:  Nat Med       Date:  2013-12-05       Impact factor: 53.440

Review 3.  Multifunctional nanoparticles for cancer immunotherapy.

Authors:  Tayebeh Saleh; Seyed Abbas Shojaosadati
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

Review 4.  Applications of nanomaterials as vaccine adjuvants.

Authors:  Motao Zhu; Rongfu Wang; Guangjun Nie
Journal:  Hum Vaccin Immunother       Date:  2014-11-17       Impact factor: 3.452

5.  Specific T cell induction using iron oxide based nanoparticles as subunit vaccine adjuvant.

Authors:  Lázaro Moreira Marques Neto; Nicholas Zufelato; Ailton Antônio de Sousa-Júnior; Monalisa Martins Trentini; Adeliane Castro da Costa; Andris Figueiroa Bakuzis; André Kipnis; Ana Paula Junqueira-Kipnis
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

6.  Encapsulation of an EP67-Conjugated CTL Peptide Vaccine in Nanoscale Biodegradable Particles Increases the Efficacy of Respiratory Immunization and Affects the Magnitude and Memory Subsets of Vaccine-Generated Mucosal and Systemic CD8+ T Cells in a Diameter-Dependent Manner.

Authors:  Bala V K Karuturi; Shailendra B Tallapaka; Pravin Yeapuri; Stephen M Curran; Sam D Sanderson; Joseph A Vetro
Journal:  Mol Pharm       Date:  2017-04-03       Impact factor: 4.939

7.  Self-encapsulating Poly(lactic-co-glycolic acid) (PLGA) Microspheres for Intranasal Vaccine Delivery.

Authors:  Brittany A Bailey; Kashappa-Goud H Desai; Lukasz J Ochyl; Susan M Ciotti; James J Moon; Steven P Schwendeman
Journal:  Mol Pharm       Date:  2017-08-22       Impact factor: 4.939

8.  Testicular biodistribution of 450 nm fluorescent latex particles after intramuscular injection in mice.

Authors:  J-P Klein; D Boudard; J Cadusseau; S Palle; V Forest; J Pourchez; M Cottier
Journal:  Biomed Microdevices       Date:  2013-06       Impact factor: 2.838

Review 9.  Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation.

Authors:  Kruti S Soni; Swapnil S Desale; Tatiana K Bronich
Journal:  J Control Release       Date:  2015-11-10       Impact factor: 9.776

Review 10.  Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects.

Authors:  Eric Dumonteil; Maria Elena Bottazzi; Peter J Hotez; Bin Zhan; Michael J Heffernan; Kathryn Jones; Jesus G Valenzuela; Shaden Kamhawi; Jaime Ortega; Samuel Ponce de Leon Rosales; Bruce Y Lee; Kristina M Bacon; Bernhard Fleischer; B T Slingsby; Miguel Betancourt Cravioto; Roberto Tapia-Conyer
Journal:  Expert Rev Vaccines       Date:  2012-09       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.